99%+ HPLC Pure | Batch-Specific Third-Party COAs | Free Shipping $250+ | Same-Day Shipping Before 2PM CT | Ships Across the US

Kynetide Research Team | Jul 16

A Global Phase II Trial Puts Peptide Immunotherapy in the Spotlight

A 2026 market-news look at the newly launched global Phase II trial of CY-101, a synthetic peptide immunotherapy for adrenocortical carcinoma, and what growing clinical validation of peptide-based immunotherapy means for the research community.

A New Phase II Milestone for Peptide Immunotherapy

Cancer Research UK is leading a newly launched global Phase II trial evaluating CY-101 (getacatetide), a synthetic peptide immunotherapy developed by the Norwegian biotechnology company Cytovation. The trial, reported in mid-July 2026, brings together Cancer Research UK, Cytovation, and the Norwegian Cancer Society to study the therapy in adrenocortical carcinoma (ACC), a rare and aggressive cancer of the adrenal gland. CY-101 is delivered directly into the tumor itself, placing it among a growing number of intratumoural peptide therapies advancing through clinical development this year.

How the Peptide Is Designed to Work

CY-101 belongs to a class of peptide immunotherapies designed to convert immune-resistant 'cold' tumors into immune-active 'hot' tumors that the body's own defenses can recognize and attack. According to reporting on the trial, the peptide stimulates local immune activity inside the tumor microenvironment while also blocking Wnt/beta-catenin signaling, a pathway frequently implicated in resistance to immunotherapy. That dual mechanism is part of why ACC, historically difficult to treat with checkpoint inhibitors alone, was selected as the trial's lead indication.

Why Adrenocortical Carcinoma Needs New Treatment Options

Adrenocortical carcinoma remains rare but disproportionately deadly. Figures cited alongside the trial announcement put UK diagnoses at roughly 350 cases a year, with around 130 deaths annually from adrenal gland cancer overall. Treatment options for advanced ACC are limited, and outcomes have changed little in recent years, which is part of the rationale for testing a mechanistically different peptide-based approach in this population.

What It Means for Peptide Research Sourcing

News like the CY-101 trial underscores how quickly peptide-based approaches are moving from bench research into late-stage clinical development across oncology, metabolic health, and tissue repair. That momentum is exactly why sourcing discipline matters more, not less, for laboratories working with peptides in a research setting. Kynetide's catalog continues to be independently verified for identity and purity through third-party HPLC testing and batch-specific Certificates of Analysis, so research teams tracking developments like CY-101 can trust the reagents behind their own bench work. Kynetide's products are supplied strictly for in-vitro and laboratory research use. They are not drugs, cosmetics, or supplements, and are not intended for human or veterinary use.

FAQ: What is CY-101 (getacatetide)?

CY-101, also referenced by the working name getacatetide, is an investigational intratumoural peptide immunotherapy developed by Cytovation. It is currently being studied in a global Phase II trial for adrenocortical carcinoma and is not an approved drug or a commercially available product.

FAQ: Is CY-101 the same as the peptides Kynetide sells?

No. CY-101 is an investigational clinical-trial drug candidate administered under medical supervision. Kynetide does not sell CY-101 or any clinical-stage therapeutic peptide. Kynetide supplies research-grade peptides intended strictly for in-vitro and laboratory research use, each verified with third-party HPLC testing and a batch-specific Certificate of Analysis.

About This Article

This content was prepared and reviewed by the Kynetide Research Team — PhD-level biochemists, peptide chemists, and laboratory scientists with backgrounds in pharmaceutical research, analytical chemistry, and regulatory science. Our team reviews primary literature, clinical studies, and regulatory filings to provide accurate, science-first content for laboratory investigators.

All Kynetide content is reviewed for scientific accuracy before publication. For research inquiries, contact us at support@kynetide.com.

Kynetide Research Team

More Posts

FDA's September 2026 Warning-Letter Sweep: What It Means for Research Peptide BuyersFDA's September 2026 Warning-Letter Sweep: What It Means for Research Peptide Buyers
FDA's September 2026 Warning-Letter Sweep: What It Means for Research Peptide Buyers

On September 1, 2026, the FDA published a coordinated set of warning letters targeting five online peptide vendors. The sweep signals that the agency is shifting from case-by-case enforcement to sector-wide scrutiny — and that a "research use only" disclaimer is no longer a regulatory shield. Here is what the letters actually say, which vendors and products were named, and what it means for labs sourcing peptides today.

The Copper Peptide (GHK-Cu) Injection Trend: What the Research Actually ShowsThe Copper Peptide (GHK-Cu) Injection Trend: What the Research Actually Shows
The Copper Peptide (GHK-Cu) Injection Trend: What the Research Actually Shows

Copper peptide serums have been a skincare staple for years, but a new trend has emerged: people are drawing GHK-Cu into syringes and injecting it at home in pursuit of firmer skin, thicker hair, and slower aging. Here's what the research actually supports, what remains unknown, and why sourcing quality matters for anyone studying this compound.

New Bill Would Direct the VA to Study Peptide Therapies for VeteransNew Bill Would Direct the VA to Study Peptide Therapies for Veterans
New Bill Would Direct the VA to Study Peptide Therapies for Veterans

On September 1, 2026, Rep. Nancy Mace introduced the PEPTIDES for Veterans Act, a bill directing the Department of Veterans Affairs to formally study peptide-based therapies for veterans receiving VA care. Here's what the bill actually does, and doesn't do, for the research community.

Peptides and Cancer Risk: What the Current Research Actually ShowsPeptides and Cancer Risk: What the Current Research Actually Shows
Peptides and Cancer Risk: What the Current Research Actually Shows

Peptides like BPC-157, TB-500, MOTS-c, KPV, epitalon, and semax have become some of the most searched compounds in longevity and biohacking circles. Social media has fueled claims that they speed healing, improve sleep, build muscle, and boost energy. But according to cancer researchers, the evidence behind many of these claims is thin, and there's an open scientific question that gets far less attention than the hype: could some peptides affect cancer risk?

Lab Tests Reveal Wild Dosing Swings in Black-Market PeptidesLab Tests Reveal Wild Dosing Swings in Black-Market Peptides
Lab Tests Reveal Wild Dosing Swings in Black-Market Peptides

An Australian lab that now spends half its time analyzing peptides bought online has found that black-market vials of a popular weight-loss peptide are just as likely to be overdosed as underdosed. The results add a new dimension to the safety debate around unapproved peptides and underscore why verified sourcing matters.

The "Looksmaxxing" Peptide Trend: What the Science Actually SaysThe "Looksmaxxing" Peptide Trend: What the Science Actually Says
The "Looksmaxxing" Peptide Trend: What the Science Actually Says

Peptides are being marketed on TikTok as a shortcut to a younger, sharper-looking face. A pharmaceutical sciences researcher explains why the hype is running well ahead of the evidence, and why sourcing and safety data matter more than ever.

Florida's Peptide Craze Is Booming — What a New Investigation FoundFlorida's Peptide Craze Is Booming — What a New Investigation Found
Florida's Peptide Craze Is Booming — What a New Investigation Found

A new Tampa Bay Times report finds that peptides have become one of Florida's fastest-growing health trends, with social media influencers driving demand for compounds marketed to ease joint pain, speed weight loss, and improve sleep. Compounding pharmacists like Dr. David Pino say order volumes have surged, raising fresh questions about oversight, purity, and who's actually formulating what people are injecting.

Trump Taps Dr. Heidi Overton to Lead the FDA — What It Could Mean for Peptide RegulationTrump Taps Dr. Heidi Overton to Lead the FDA — What It Could Mean for Peptide Regulation
Trump Taps Dr. Heidi Overton to Lead the FDA — What It Could Mean for Peptide Regulation

President Trump has picked Dr. Heidi Overton, a physician and White House health policy aide, as his nominee to lead the FDA. If confirmed by the Senate, she would inherit one of the agency's most closely watched open questions: what happens next for peptides like BPC-157 and TB-500 after this summer's advisory panel vote.

Who's Actually Watching for Peptide Side Effects?Who's Actually Watching for Peptide Side Effects?
Who's Actually Watching for Peptide Side Effects?

Peptides are everywhere on social media, but most of the unapproved products behind the hype have never been checked for what's actually in the vial. A new public-health review breaks down the safety gaps regulators are racing to close, and why sourcing verification matters more than ever.